An observational study in Gynecologic Cancer, Radiotherapy Side Effect and Radiotherapy; Complications, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to female participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by IRCCS San Raffaele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Radiation Injuries with a site in Italy — 7 open to participants now, 8 under way, none of them phase 3. Radiation Injuries · Italy.
Among the 12 studies in Radiation Injuries with a site in Italy, this one is the 3rd largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2024, is one of 10 observational ones, and was the 8th registered.
328 studies on the registry are indexed under Radiation Injuries; 96 are open to participants now.
Browse Radiation Injuries studies →7 of the 12 studies in Radiation Injuries with a site in Italy are open now. Recruiting first, the newest first:
Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Sites in Italy
Ages 18+
CNAO National Center of Oncological Hadrontherapy · Sites in Italy
University of Milano Bicocca · Sites in Italy
Ages 18–90 · Men only
Centro di Riferimento Oncologico - Aviano · Sites in Italy
European Institute of Oncology · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 76 Radiation Injuries studies recruiting now, 52 (68%) set no upper age limit and 14 (18%) stop at 75 or younger; 8 take children under 18; 2 take healthy volunteers.
This study: 18 Years to 90 Years · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2024.
This study's planned enrollment of 1,000 is above the median of 130 across 96 observational studies indexed under Radiation Injuries.
Median enrollment 27 across the 2 interventional studies, 220 across the 10 observational. Of the 3 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 10 most frequent:
IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.
IRCCS San Raffaele has 1 study filed under Radiation Injuries — fewer than ten, so there is no comparison to draw.
2 of the studies in Radiation Injuries with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06306170IRCCS San RaffaeleAdvanced Radiotherapy (ART) in Gynecological Cancer Patients (GYN-ART) | 2027-02-15 |
| NCT07129525Fondazione Policlinico Universitario Agostino Gemelli IRCCSHealth Oriented Protocol for Epidermal Radiodermatitis | 2027-03-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 12 studies in Radiation Injuries with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational mono-institutional study. Patients with gynecologic tumors treated with advanced radiotherapy- Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Body Radiotherapy (SBRT)- will be included and toxicity and outcomes analyzed.
The patients with gynecological cancer treated with Advanced Radiotherapy (ART)- Image Guided Radiotherapy (IGRT), Intensity Modulated Radiotherapy (IMRT), Stereotactic Body Radiotherapy (SBRT)- at the Department of Radiotherapy of "IRCCS San Raffaele Scientific Institute" (IRCCSSRaffaele) from January 2005 to January 2024 will be identified and their clinical and dosimetric data retrieved and analyzed.
The study objectives are the analysis of acute and late toxicity, and clinical outcomes, such as local, regional and distant control,disease free survival, cancer-specific survival, and overall survival. Secondary objective is the identification of prognostic factors for toxicity, disease progression, survival, including radiomic characteristics.
Gynecologic cancer patients, > 18 years old, treated with IGRT, IMRT, SBRT
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Gynecologic cancer patients treated with IGRT, IMRT, SBRT (advanced radiotherapy-ART)
Radiation: Image Guided Radiotherapy
Patients treated with IGRT, IMRT, SBRT for Gynecological cancer will be evaluated
Also known as: Intensity Modulated Radiotherapy, Stereotactic Body Radiotherapy
Local Relapse Free Survival
local control (on the treated site) of the disease
Time frame: From date of radiotherapy end until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months
Regional Relapse Free Survival
regional control (regional lymph nodal chain) of the disease
Time frame: From date of radiotherapy end until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months
Distant Metastases Free Survival
distant metastases developed after the treatment
Time frame: From date of radiotherapy end until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months
Disease Free Survival
absence of disease progression during the follow-up
Time frame: From date of radiotherapy end until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 120 months
Overall Survival
survival from all causes
Time frame: From date of radiotherapy end until the date of death from any cause, assessed up to 120 months
Cancer Specific Survival
cancer survival
Time frame: From date of radiotherapy end until the date of death from disease progression, assessed up to 120 months
Acute toxicity
Toxicity developed in the first three months after the treatment, assessed with Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale, which displayes grades from 1 to 5, with grade 1 meaning mild toxicity and grade 5 death related to toxicity
Time frame: Up to three months from the start of radiotherapy
Late toxicity
Toxicity developed after three months until the end of follow-up or death, assessed with Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale, assessed with Common Terminology Criteria for Adverse Events (CTCAE) v5.0 scale, which displayes grades from 1 to 5, with grade 1 meaning mild toxicity and grade 5 death related to toxicity
Time frame: From three months after the start of radiotherapy until the end of follow-up or death, assessed up to 120 months
Predictive factors for disease progression and death
Factors predicting survival. Survival trees, univariate/multivariate Cox regression models will be estimated to identify potential risk factors associated with survival outcomes
Time frame: From radiotherapy end to date of local, regional progression, distant failure, or death, assessed up to 120 months
Radiomic predictive factors for disease progression and death
CT and PET/CT radiomic features predicting relapse or death will be extracted, acording to IBSI (Image Biomarker Standardisation Initiative), owning to the different families of features: Morphology, Statistical, Intensity Histogram, Grey Level Cooccurrence Matrix 3D-average, Grey Level Co-occurrence Matrix 3D-combined, Grey Level Run Lenght 3D-average. Grey Level Run Lenght 3D\_combined, Grey Level Size Zone Matrix 3D, Neighbors Grey Tone Difference Matrix 3D, Grey Level Distance Zone Matrix 3D, standard convolutional filters within radiomic workflow (wavelets, Laplacian of Gaussian)
Time frame: From radiotherapy end to the first registered event (disease progression or death), assessed up to 120 months
Plan to share: Yes — The data that support the findings of this study (anonymized individual participant data) are available on request from the corresponding author to researchers who provide a methodologically sound proposal. Requests made to the corresponding author (AF) will be evaluated by the Lombardy Territorial Ethics Committee
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: for another 2 years after the closure of the study
Access criteria: request from the corresponding author approved by the Lombardy Territorial Ethics Committee
Started Feb 2024 (actual). Primary completion is estimated for Feb 2027, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.